| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Executive Officer
3 companies
Greenleaf Peter is a Chief Executive Officer at AUPH, with reported holdings spanning 3 companies. Recent filings cover 3 purchases and 10 sales. Those positions are worth an estimated $26.6M at current prices.
Our model assigns Greenleaf Peter a below-average insider score of 49/100, based on 6 past trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -28.0%.
Greenleaf Peter's largest disclosed position is in AUPH as Chief Executive Officer, worth about $26.2M. The recent filings there lean toward selling, a net 524,214 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | PTHS Pelthos Therapeutics Inc. | Director | Sell | 797 | $21.17 | $16,872.49 | -3.3% | - | - | |
| Jul 2, 2026 | PTHS Pelthos Therapeutics Inc. | Director | Sell | 797 | $26.13 | $20,826.96 | -3.2% | -18.5% | - | |
| Apr 2, 2026 | PTHS Pelthos Therapeutics Inc. | Director | Sell | 797 | $20.92 | $16,669.59 | -3.1% | +37.3% | - | |
| Mar 4, 2025 | AUPH Aurinia Pharmaceuticals Inc. | Chief Executive Officer | Sell | 360,540 | $7.96 | $2,871,124.24 | -16.8% | -1.5% | +86.1% | |
| Mar 6, 2024 | AUPH Aurinia Pharmaceuticals Inc. | Chief Executive Officer | Sell | 126,981 | $5.60 | $711,093.60 | -7.7% | -4.5% | +48.4% | |
| Mar 2, 2023 | AUPH Aurinia Pharmaceuticals Inc. | Chief Executive Officer | Sell | 32,750 | $8.94 | $292,785.00 | -3.2% | +0.2% | -35.3% | |
| Mar 2, 2022 | AUPH Aurinia Pharmaceuticals Inc. | Chief Executive Officer | Sell | 9,068 | $12.01 | $108,906.68 | -21.6% | -2.9% | -23.1% | |
| May 11, 2021 | AUPH Aurinia Pharmaceuticals Inc. | Chief Executive Officer | Buy | 5,125 | $10.71 | $54,891.07 | +61.5% | +39.7% | -14.7% | |
| May 18, 2018 | AVTX Avalo Therapeutics, Inc. | Chief Executive Officer | Buy | 12,500 | $3.98 | $49,750.00 | +3.1% | - | - |